[go: up one dir, main page]

WO2019035668A3 - 중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물 - Google Patents

중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물 Download PDF

Info

Publication number
WO2019035668A3
WO2019035668A3 PCT/KR2018/009417 KR2018009417W WO2019035668A3 WO 2019035668 A3 WO2019035668 A3 WO 2019035668A3 KR 2018009417 W KR2018009417 W KR 2018009417W WO 2019035668 A3 WO2019035668 A3 WO 2019035668A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
associated ophthalmopathy
mesenchymal stem
thyroid associated
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009417
Other languages
English (en)
French (fr)
Other versions
WO2019035668A9 (ko
WO2019035668A2 (ko
Inventor
유혜린
박미라
김기진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Original Assignee
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University filed Critical Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Priority to JP2020508318A priority Critical patent/JP7168653B2/ja
Priority to US16/639,319 priority patent/US11524036B2/en
Priority to EP18845495.3A priority patent/EP3669884B1/en
Publication of WO2019035668A2 publication Critical patent/WO2019035668A2/ko
Publication of WO2019035668A3 publication Critical patent/WO2019035668A3/ko
Publication of WO2019035668A9 publication Critical patent/WO2019035668A9/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

중간엽 줄기세포를 유효성분으로 포함하는 갑상선 안질환을 예방, 개선, 또는 치료하기 위한 조성물을 제공한다. 중간엽 줄기세포를 유효성분으로 포함하는 갑상선 안질환을 치료하기 위한 약학적 조성물은 갑상선 안질환 환자의 안와 섬유아세포의 비정상적인 히알루론산 생성 증가, 지방세포 분화 증가, 및 지질 축적 증가를 회복시키므로, 갑상선 안질환 치료에 유용하게 이용될 수 있다.
PCT/KR2018/009417 2017-08-16 2018-08-16 중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물 Ceased WO2019035668A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020508318A JP7168653B2 (ja) 2017-08-16 2018-08-16 間葉系幹細胞を含む甲状腺眼症を治療するための組成物
US16/639,319 US11524036B2 (en) 2017-08-16 2018-08-16 Method for treating thyroid associated ophthalmopathy
EP18845495.3A EP3669884B1 (en) 2017-08-16 2018-08-16 Composition for treatment of thyroid associated ophthalmopathy, comprising mesenchymal stem cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0103723 2017-08-16
KR20170103723 2017-08-16

Publications (3)

Publication Number Publication Date
WO2019035668A2 WO2019035668A2 (ko) 2019-02-21
WO2019035668A3 true WO2019035668A3 (ko) 2019-05-16
WO2019035668A9 WO2019035668A9 (ko) 2019-07-04

Family

ID=65362766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009417 Ceased WO2019035668A2 (ko) 2017-08-16 2018-08-16 중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물

Country Status (5)

Country Link
US (1) US11524036B2 (ko)
EP (1) EP3669884B1 (ko)
JP (1) JP7168653B2 (ko)
KR (12) KR102178303B1 (ko)
WO (1) WO2019035668A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201914235D0 (en) * 2019-10-02 2019-11-13 Univ Liverpool Cell populations and methods of preparing same
KR102348920B1 (ko) * 2021-01-22 2022-01-11 메디포스트(주) Ptx-3, timp1 및 bdnf를 발현하는 간엽줄기세포를 유효성분으로 포함하는 염증 질환 또는 통증의 예방 또는 치료용 약학 조성물
WO2023054918A1 (ko) 2021-09-30 2023-04-06 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
WO2023080413A1 (ko) * 2021-11-02 2023-05-11 주식회사 디자인셀 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물
CN117503799B (zh) * 2023-11-15 2024-05-28 数字辉煌(北京)科技有限公司 一种脐带间充质干细胞上清液的制备方法及其在眼腺体修复中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065639A1 (en) * 2015-09-03 2017-03-09 Escape Therapeutics, Inc. Mesenchymal stem cells with enhanced immunosuppressive capability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828376B2 (en) * 2008-08-20 2014-09-09 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
ES2727030T3 (es) 2010-08-23 2019-10-11 Kang Stem Biotech Co Ltd Composición farmacéutica para prevenir o tratar enfermedades inmunitarias o enfermedades inflamatorias, que contiene células madre tratadas con agonista de NOD2 o un producto cultivado del mismo
US20130251670A1 (en) * 2011-09-13 2013-09-26 Aidan Products, Inc Treatment of Macular Edema Utilizing Stem Cell and Conditioned Media Thereof
WO2016117960A1 (ko) * 2015-01-23 2016-07-28 가톨릭대학교 산학협력단 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도
CN106479969B (zh) 2016-10-13 2019-10-11 博雅干细胞科技有限公司 使用hla-g阳性间充质干细胞治疗系统性红斑狼疮的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065639A1 (en) * 2015-09-03 2017-03-09 Escape Therapeutics, Inc. Mesenchymal stem cells with enhanced immunosuppressive capability

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASTRO-MANRREZA, MARTA ELENA: "Participation of Mesenchymal Stem Cells in the Regulation of Immune Response and Cancer Development", BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, vol. 73, no. 6, 30 November 2016 (2016-11-30) - December 2016 (2016-12-01), pages 380 - 387, XP055608746, ISSN: 1665-1146, DOI: 10.1016/j.bmhimx.2016.10.003 *
EL OMAR, REINE ET AL.: "Umbilical Cord Mesenchymal Stem Cells: the New Gold Standard for Mesenchymal Stem Cell -based Therapies?", TISSUE ENGINEERING: PART B, vol. 20, no. 5, 22 April 2014 (2014-04-22), pages 523 - 544, XP055608738, ISSN: 1937-3368, DOI: 10.1089/ten.teb.2013.0664 *
KOZDON, KATARZYNA ET AL.: "Mesenchymal Stem Cell -like Properties of Orbital Fibroblasts in Graves' Orbitopatby", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 56, no. 10, September 2015 (2015-09-01), pages 5743 - 5750, XP055608733, DOI: 10.1167/iovs.15-16580 *
LEE, JUNG MIN ET AL.: "Comparison of Immunomodulatory Effects of Placenta Mesenchymal Stem Cells with Bone Marrow and Adipose Mesenchymal Stem Cells", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 13, 2012, pages 219 - 224, XP028502794, DOI: doi:10.1016/j.intimp.2012.03.024 *
ZHAO, CHENG ET AL.: "Umbilical Cord-derived Mesenchymal Stem Cells Inhibit Cadherin-11 Expression by Fibroblast-like Synoviocytes in Rheumatoid Arthritis", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, 2015, pages 1 - 10, XP055608743, ISSN: 2314-8861, DOI: 10.1155/2015/137695 *

Also Published As

Publication number Publication date
EP3669884B1 (en) 2023-10-18
JP7168653B2 (ja) 2022-11-09
KR20200125556A (ko) 2020-11-04
KR20200124199A (ko) 2020-11-02
KR20200125555A (ko) 2020-11-04
JP2020530304A (ja) 2020-10-22
WO2019035668A9 (ko) 2019-07-04
KR102190992B1 (ko) 2020-12-15
KR102191000B1 (ko) 2020-12-15
KR102190998B1 (ko) 2020-12-15
KR102190995B1 (ko) 2020-12-15
KR20200124204A (ko) 2020-11-02
US20200246392A1 (en) 2020-08-06
KR102190993B1 (ko) 2020-12-15
KR102190999B1 (ko) 2020-12-15
EP3669884A2 (en) 2020-06-24
KR102190997B1 (ko) 2020-12-15
KR20200124202A (ko) 2020-11-02
KR102190994B1 (ko) 2020-12-15
US11524036B2 (en) 2022-12-13
EP3669884A4 (en) 2021-05-19
KR20200124201A (ko) 2020-11-02
KR102190991B1 (ko) 2020-12-15
KR20200124206A (ko) 2020-11-02
KR20200124203A (ko) 2020-11-02
KR102190996B1 (ko) 2020-12-15
KR20200124207A (ko) 2020-11-02
KR20200124200A (ko) 2020-11-02
KR20190019032A (ko) 2019-02-26
KR20200124205A (ko) 2020-11-02
KR102190990B1 (ko) 2020-12-15
WO2019035668A2 (ko) 2019-02-21
KR102178303B1 (ko) 2020-11-13

Similar Documents

Publication Publication Date Title
WO2019035668A3 (ko) 중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물
CA2835291C (en) Topical skin composition comprising centella asiatica stem cells and tripeptide-1
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
PH12015500106A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
HK1218836A1 (zh) 协同细菌组合物和其制造方法和用途
TN2015000169A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MX2014009657A (es) Pilar dental para el soporte de protesis dentales y metodo de fabricacion del mismo.
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
WO2013060771A3 (en) Composition containing an extract of a sequential or simultaneous fermentation
WO2017211371A3 (en) Calr and jak2 vaccine compositions
WO2011090297A3 (ko) 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
GB201119261D0 (en) Morus extracts rich in n-acids of imino sugars and or pipecolic acids
CA2970993C (en) GENETICALLY MODIFIED MESENCHYMATOUS STEM CELLS EXPRESSING ALPHA-1-ANTITRYPSIN (AAT)
MX2016006727A (es) Composiciones farmaceuticas con actividad hidratante y lubricante.
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2022008273A (es) Neurregulina para usarse en el tratamiento de lesion cardiaca.
WO2012020989A3 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
IN2015DN02650A (ko)
WO2016108634A3 (ko) 표피성장인자와 리포좀의 하이브리드형 다중층 나노구조체 및 그 제조방법
WO2015089228A3 (en) Compositions and methods for producing and administering brown adipocytes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18845495

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020508318

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018845495

Country of ref document: EP

Effective date: 20200316